Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study (THYGEMOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02472080
Recruitment Status : Terminated (inefficiency)
First Posted : June 15, 2015
Last Update Posted : March 18, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Radioiodine refractory differentiated thyroid cancer is a rare tumor and therapeutic options are limited in this setting. Molecular targeted therapies have recently been developed for progressive disease and demonstrated clinical activity, especially with anti-angiogenic agents.

For patients with contra-indication to these agents or in case of progression or toxicity during treatment, chemotherapy is usually proposed but this strategy has not been validated by prospective data.

The investigators propose to conduct an open single arm phase 2 study to evaluate response rate according to RECIST 1.1 with GEMOX regimen (gemcitabine - oxaliplatin combination) for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.


Condition or disease Intervention/treatment Phase
Thyroid Cancer Drug: gemcitabine -oxaliplatine combination Phase 2

Detailed Description:

The aim is to study efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.

For refractory thyroid cancer patients, in case of contra-indication to molecular targeted therapies or in case of progression or toxicity during treatment, alternative treatments are urgently needed.

Our study could precise if cytotoxic agents should remain a treatment option for refractory thyroid cancer after molecular targeted therapies or in case of contra-indication.

Numerous clinical trials are proposed to evaluate various molecular targeted therapies for refractory thyroid cancer, either conducted by institutional or industrial promoters. In contrast, chemotherapy trials are lacking. As generics are actually available for gemcitabine and oxaliplatin, no industrial support can be expected and prospective evaluation a chemotherapy regimen need to be conducted by an institutional promoter ("Assistance Publique - Hôpitaux de Paris"), supported by many French expert teams through the rare tumor network ""TUTHYREF"".

GEMOX regimen will be administrated intravenously every two weeks in ambulatory setting.

The objective of this study is to analyse the efficacy of chemotherapy with gemcitabine - oxaliplatin combination for advanced radioiodine refractory differentiated thyroid cancer patients after anti-angiogenic agents or in case of contra-indication to anti-angiogenic therapy.

The primary end point is overall response rate (complete + partial response - CR+PR), according to RECIST 1.1, assessed by local investigator at 4 months.

30 patients will be included in a two steps design (Fleming design). A response rate lower than 15% define the inefficacy level. Minimal efficacy should be 35% response rate.

First step: inclusion of 15 patients. If 2 or less responses are observed: end of study for inefficacy If 6 or more responses are observed: efficacy endpoint has been reached If 3 to 5 responses are observed, additional inclusions are needed. Second step: inclusion of 15 additional patients. Nine responses are expected to define a positive study. Details are presented in statistical section.

The secondary end points are:

  • Safety report according to NCI CTCAE v 4.0 grading scale
  • Early metabolic response rate on 18F-FDG-PET/CT at 2 months
  • Disease control rate (DCR = CR + PR + SD) ≥ 6 months
  • Duration of response
  • Time to progression
  • Progression free survival
  • Overall survival.
  • Evolution of quality of life according to Fact-G and EQ-5D "

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients
Actual Study Start Date : April 7, 2016
Actual Primary Completion Date : April 1, 2018
Actual Study Completion Date : January 15, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: gemcitabine -oxaliplatine combination Drug: gemcitabine -oxaliplatine combination
gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles




Primary Outcome Measures :
  1. overall response rate [ Time Frame: 4 months ]
    overall response rate measured (complete and partial responses) by CT-scan according to RECIST criteria v1.1


Secondary Outcome Measures :
  1. number of adverse events and serious adverse events (AE) according to CTCAE v4.03 [ Time Frame: up to 12 month ]
    recording number of adverse events and serious adverse events (AE) according to CTCAE v4.03, during chemotherapy and follow up.

  2. Early metabolic response rate on 18F-FDG-TEP/CT [ Time Frame: 2 months ]
    semi-quantitative PET Response Criteria in Solid Tumors PERCIST1.0 "modified" using SUVmax and body-weight. Central reviewing of FDG-PET data by two readers at the end of the study will be done.

  3. Disease control rate [ Time Frame: 4 months ]
    Disease control rate (DCR) is defined as the percentage of patients who have achieved complete response (CR), partial response (PR) or stable disease (SD).

  4. Time to progression [ Time Frame: up to 36 months ]
    Time from documentation of tumor response to disease progression or date of death from any cause

  5. Progression free survival [ Time Frame: up to 36 months ]
    Time from documentation of tumor response to disease progression or date of death from any cause

  6. Overall survival [ Time Frame: up to 36 months ]
    Delay between inclusion and death from any cause

  7. Quality of life [ Time Frame: at day 1(week 1, i.e first cycle) and repeated every 28 days (i.e at W5, W9, W13, W17) during chemotherapy and every 3 months until 12 months ]
    evolution of quality of life will be assessed by the scores at the FACT-G and EQ-5D surveys (French version)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

"Main Inclusion criteria

  1. Histologically confirmed differentiated or poorly differentiated thyroid cancer that is metastatic or unresectable
  2. Patients refractory to radio iodine
  3. Radiologic evidence of clinically relevant disease progression (as per RECIST 1.1)
  4. Measurable disease (by RECIST Version 1.1 criteria)
  5. ECOG performance status of ≤ 1
  6. Adequate hematologic, renal and liver function
  7. Negative serum pregnancy test in premenopausal women.
  8. Signed informed consent

Main Non-Inclusion criteria

  1. Other histological subtypes of thyroid tumors: anaplastic, medullary, lymphoma or sarcoma
  2. Active CNS metastases
  3. Prior chemotherapy. Patients treated previously with molecular targeted therapies could be included.
  4. Severe, acute or chronic medical or psychiatric condition or laboratory abnormality which in the judgment of the investigator would make the patient inappropriate for entry into this study"

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02472080


Locations
Layout table for location information
France
Groupe Hospitalier Pitié Salpetriere
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Laurence Leenhardt Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02472080    
Other Study ID Numbers: P130933
First Posted: June 15, 2015    Key Record Dates
Last Update Posted: March 18, 2019
Last Verified: March 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Gemcitabine
Oxaliplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs